D. Aldrighetti

462 total citations
19 papers, 326 citations indexed

About

D. Aldrighetti is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Aldrighetti has authored 19 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Aldrighetti's work include Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (11 papers) and Breast Cancer Treatment Studies (8 papers). D. Aldrighetti is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), HER2/EGFR in Cancer Research (11 papers) and Breast Cancer Treatment Studies (8 papers). D. Aldrighetti collaborates with scholars based in Italy, United States and Belgium. D. Aldrighetti's co-authors include Angelo Bolognesi, A. Rubagotti, Francesco Boccardo, P Sismondi, A. Farris, M. Mesiti, D. Amoroso, P Pacini, V. Distante and Franco Tarro Genta and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

D. Aldrighetti

18 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Aldrighetti Italy 8 230 181 122 56 41 19 326
André Mattar Brazil 9 141 0.6× 83 0.5× 63 0.5× 40 0.7× 49 1.2× 46 292
V. Labonia Italy 8 169 0.7× 126 0.7× 81 0.7× 47 0.8× 27 0.7× 16 246
Bernard Lespérance Canada 11 182 0.8× 91 0.5× 145 1.2× 31 0.6× 177 4.3× 17 387
Amber N. Hurson United Kingdom 4 220 1.0× 106 0.6× 292 2.4× 48 0.9× 75 1.8× 4 492
Ángel Guerrero Spain 6 198 0.9× 130 0.7× 62 0.5× 105 1.9× 47 1.1× 27 258
Salina Chan United States 6 127 0.6× 144 0.8× 203 1.7× 34 0.6× 112 2.7× 9 319
Brittany Bychkovsky United States 11 139 0.6× 107 0.6× 93 0.8× 35 0.6× 40 1.0× 37 286
Charles L. Wiggins United States 8 202 0.9× 139 0.8× 32 0.3× 66 1.2× 126 3.1× 12 330
Claudia Lefeuvre France 6 152 0.7× 212 1.2× 109 0.9× 134 2.4× 77 1.9× 15 374
Débora S. Bruno United States 12 215 0.9× 82 0.5× 21 0.2× 128 2.3× 51 1.2× 45 352

Countries citing papers authored by D. Aldrighetti

Since Specialization
Citations

This map shows the geographic impact of D. Aldrighetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Aldrighetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Aldrighetti more than expected).

Fields of papers citing papers by D. Aldrighetti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Aldrighetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Aldrighetti. The network helps show where D. Aldrighetti may publish in the future.

Co-authorship network of co-authors of D. Aldrighetti

This figure shows the co-authorship network connecting the top 25 collaborators of D. Aldrighetti. A scholar is included among the top collaborators of D. Aldrighetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Aldrighetti. D. Aldrighetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Naldini, Matteo Maria, Giulia Viale, Alessia Rognone, et al.. (2024). Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice. Frontiers in Oncology. 14. 1374547–1374547. 4 indexed citations
2.
Licata, Luca, Giulia Viale, Stefania Zambelli, et al.. (2023). 2090P Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice. Annals of Oncology. 34. S1098–S1098.
3.
Viale, Giulia, Luca Licata, Stefania Zambelli, et al.. (2020). Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. The Oncologist. 25(7). e1013–e1020. 28 indexed citations
4.
Rugo, Hope S., Mario Campone, Dino Amadori, et al.. (2013). A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 139(2). 411–419. 19 indexed citations
5.
Cardoso, Fátima, Jean‐Luc Canon, Dino Amadori, et al.. (2012). An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast. 21(6). 716–723. 12 indexed citations
6.
Giovannini, Monica, et al.. (2010). Antiangiogenic strategies in breast cancer management. Critical Reviews in Oncology/Hematology. 76(1). 13–35. 18 indexed citations
7.
Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120. Cancer Research. 69(2). 1 indexed citations
8.
Cardoso, Fátima, J.-L. Canon, D. Amadori, et al.. (2009). 5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer. European Journal of Cancer Supplements. 7(2). 283–283. 2 indexed citations
9.
Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.. Cancer Research. 69(2_Supplement). 4120–4120. 3 indexed citations
10.
Dirix, Luc, Jean Luc Canon, D. Amadori, et al.. (2009). An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+ Advanced Breast Cancer (ABC).. Cancer Research. 69(24_Supplement). 6088–6088. 4 indexed citations
11.
Boccardo, Francesco, A. Rubagotti, D. Aldrighetti, et al.. (2007). Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Cancer. 109(6). 1060–1067. 19 indexed citations
12.
Moliterni, Angela, Mauro Mansutti, D. Aldrighetti, et al.. (2007). Anthracycline-based sequential adjuvant chemotherapy in operable breast cancer: Five-year results of a randomized study by the Michelangelo Foundation. Journal of Clinical Oncology. 25(18_suppl). 535–535. 1 indexed citations
13.
Boccardo, Francesco, A. Rubagotti, D. Aldrighetti, et al.. (2007). O-54 Switching to an aromatase inhibitor provides mortality benefit in early breast-carcinoma: Pooled analysis of 2 consecutive trials. European Journal of Cancer Supplements. 5(3). 17–17. 1 indexed citations
14.
Baldini, Editta, Tiziana Prochilo, B. Salvadori, et al.. (2004). Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety. British Journal of Cancer. 91(1). 45–49. 24 indexed citations
15.
Conté, Pierfranco, Valentina Guarneri, Paolo Bruzzi, et al.. (2004). Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma. Cancer. 101(4). 704–712. 50 indexed citations
16.
17.
18.
Boccardo, Francesco, D. Amoroso, A. Rubagotti, et al.. (1993). Endocrine Therapy of Breast Cancer. Annals of the New York Academy of Sciences. 698(1). 318–328. 7 indexed citations
19.
Volterrani, F, D. Aldrighetti, Angelo Bolognesi, et al.. (1991). [Analysis of the results of 264 cases of small breast carcinoma treated with conservative surgery and radiotherapy].. PubMed. 82(3). 322–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by André Mattar Breakdown of academic impact, for papers by V. Labonia Breakdown of academic impact, for papers by Bernard Lespérance Breakdown of academic impact, for papers by Amber N. Hurson Breakdown of academic impact, for papers by Ángel Guerrero Breakdown of academic impact, for papers by Salina Chan Breakdown of academic impact, for papers by Brittany Bychkovsky Breakdown of academic impact, for papers by Charles L. Wiggins Breakdown of academic impact, for papers by Claudia Lefeuvre Breakdown of academic impact, for papers by Débora S. Bruno
Rankless by CCL
2026